Wedbush cuts Foghorn Therapeutics stock rating on drug setback
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral, lowering its price target to $2.00. The move follows the discontinuation of FHD-909, a drug in collaboration with Eli Lilly, due to Phase 1 data. Foghorn is cutting 40% of its workforce and realigning operations. Other analysts have also lowered price targets, though some maintain positive ratings.
How this was made
The 30-second read
Why it matters
The news triggered analyst downgrades and a sharp price target reduction, indicating heightened downside risk.
Market read
The setback is a primary catalyst for FHTX's stock movement, with potential spillover to peers targeting synthetic lethality pathways.
What to watch
Cash runway extended to 2029 and strong liquidity could support future R&D spending.
Background
Foghorn Therapeutics announced the discontinuation of its lead SMARCA2 inhibitor after Phase 1 data failed to meet efficacy expectations, ending its partnership with Eli Lilly.
Ticker impact
Wedbush downgraded FHTX to Neutral and cut its price target after the company halted its lead drug FHD-909 following disappointing Phase 1 data.
downward pressure as investors price in the halted program and reduced guidance
Analyst downgrade, 40% workforce cut, and termination of a key collaboration are fresh, material events that typically drive the share price down.
Market effects
Biotech sector may see broader risk aversion as drug failures raise concerns about SMARCA2 targets.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the company can successfully pivot to its wholly‑owned pipeline, the stock may be undervalued after the sell‑off.
Key entities
- companyFoghorn Therapeutics
Biotech firm developing SMARCA2/4 inhibitors.
- companyEli Lilly
Partner in the discontinued drug program.